- Home
- URGN vs ETW Comparison
URGN vs ETW Comparison
Compare URGN & ETW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- URGN
- ETW
- Stock Information
- Founded
- URGN 2004
- ETW 2005
- Country
- URGN United States
- ETW United States
- Employees
- URGN N/A
- ETW N/A
- Industry
- URGN Biotechnology: Pharmaceutical Preparations
- ETW Investment Managers
- Sector
- URGN Health Care
- ETW Finance
- Exchange
- URGN Nasdaq
- ETW Nasdaq
- Market Cap
- URGN 831.6M
- ETW 939.4M
- IPO Year
- URGN 2017
- ETW N/A
- Fundamental
- Price
- URGN $19.22
- ETW $8.71
- Analyst Decision
- URGN Strong Buy
- ETW
- Analyst Count
- URGN 8
- ETW 0
- Target Price
- URGN $29.00
- ETW N/A
- AVG Volume (30 Days)
- URGN 1.3M
- ETW 284.6K
- Earning Date
- URGN 08-07-2025
- ETW 01-01-0001
- Dividend Yield
- URGN N/A
- ETW 8.61%
- EPS Growth
- URGN N/A
- ETW N/A
- EPS
- URGN N/A
- ETW N/A
- Revenue
- URGN $91,871,000.00
- ETW N/A
- Revenue This Year
- URGN $39.80
- ETW N/A
- Revenue Next Year
- URGN $108.94
- ETW N/A
- P/E Ratio
- URGN N/A
- ETW N/A
- Revenue Growth
- URGN 8.98
- ETW N/A
- 52 Week Low
- URGN $3.42
- ETW $6.96
- 52 Week High
- URGN $19.69
- ETW $8.49
- Technical
- Relative Strength Index (RSI)
- URGN 76.29
- ETW 56.79
- Support Level
- URGN $18.37
- ETW $8.64
- Resistance Level
- URGN $19.36
- ETW $8.77
- Average True Range (ATR)
- URGN 1.03
- ETW 0.07
- MACD
- URGN 0.25
- ETW -0.01
- Stochastic Oscillator
- URGN 91.26
- ETW 75.93
About URGN UroGen Pharma Ltd.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.
About ETW Eaton Vance Corporation Eaton Vance Tax-Managed Global Buy-Write Opportunites Fund of Beneficial Interest
Eaton Vance Tax-mangd Glo Buy-write Oppo is a United States-based diversified, closed-end management investment company. The primary investment objective of the company is to provide current income and gains. The secondary objective of the fund is capital appreciation. The fund invests in a diversified portfolio of common stocks and writes call options on one or more U.S. indices on a substantial portion of the value of its common stock portfolio to generate current earnings from the option premium. Its portfolio of investments consists of capital markets, chemicals, banks, biotechnology, media, and other sectors.